4SC - Domatinostat R&D ramp-up in H218
During the Q218 results call, 4SC management announced that with current funds, it plans to initiate some of its additional domatinostat trials...
189 Views
4SC - Yakult starts Phase II trial; fresh 4SC-202 data
Yakult, 4SC’s development partner for resminostat in Japan, has reached two clinical development milestones. First, just two weeks after it joined...
94 Views
4SC - Yakult joined the pivotal RESMAIN study
Together with its Q417 results announced last week, 4SC also reported progress with its R&D activities. All three lead assets – resminostat,...
98 Views
4SC - Steady R&D newsflow
Over the past several months 4SC has reported progress with both its clinical-stage assets – resminostat and 4SC-202. The pivotal trial with...
114 Views
Becoming a dermato-oncology expert
4SC’s new core strategy revealed earlier this year has focused on dermato-oncological indications, while its assets for other indications are...
182 Views